ZUG, SWITZERLAND -- Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, published the invitation and agenda for its 2026 Annual General Meeting (AGM), which will be held virtually on April 22, 2026, at 3:00pm CEST.

Dividend proposal

The Board of Directors proposes a dividend of 0.35 CHF per registered share of Galderma following its record 2025 performance. If approved by shareholders, the dividend will be paid out of reserves from capital contributions and, in accordance with applicable tax regulations, will be free from Swiss withholding tax.

Proposed elections to the Board of Directors of Galderma Group AG

As previously announced, and in connection with L’Oréal’s increased investment in Galderma, the Board members representing the consortium led by EQT, Michael Bauer and Marcus Brennecke, will not stand for re-election and will step down from the Board at the conclusion of the 2026 AGM. Delphine Viguier-Hovasse, Chief Innovation & Prospective Officer at L’Oréal, and Samuel du Retail, Managing Director of Artificial Intelligence, Data and Shared Services at L’Oréal, will be proposed by L’Oréal to shareholders for election as non-independent members.

The Board of Directors will also propose the appointment of Harry Kirsch, former Chief Financial Officer of Novartis, as a new independent member, as well as the re-election of the following current members, each for a one-year term until the completion of the next AGM:

·Thomas Ebeling (Chair)
·Daniel Browne
·Maria Teresa Hilado
·Karen Lee Ling
·Roberto Marques
·Sherilyn McCoy
·Flemming Ørnskov, M.D., MPH

“On behalf of the Board, I would like to sincerely thank Michael Bauer and Marcus Brennecke for their commitment and valuable contributions throughout their tenure. The proposed elections of Harry Kirsch, Delphine Viguier-Hovasse and Samuel du Retail bring a strong and complementary range of experience to Galderma, spanning financial and strategic leadership, consumer and sustainability-focused perspectives, and innovation and advanced technology. The Board looks forward to the contributions they would bring as Galderma advances its ambition to be the undisputed dermatology powerhouse.”

THOMAS EBELING
CHAIR OF THE BOARD OF DIRECTORS
GALDERMA